ArticleCureus2024
Cardiotoxicity of BRAF/MEK Inhibitors Mimicking Apical Hypertrophic Cardiomyopathy.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Role of SGLT2 inhibitors in cancer therapy-related cardiac dysfunction (CTRCD) in adults: systematic review and meta-analysis: SGLT2 inhibitors and CTRCD.Naunyn-Schmiedeberg's archives of pharmacology · 2026Pooled it
- Systemic Melanoma Therapy in Patients with Pre-Existing Heart Failure: An HF-Centered Decision Framework and Critical Narrative Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardio-oncology is a new and fast-evolving collaborative subdiscipline of cardiology whose goal is to increase the quality and length of the lives of oncological patients with precise prophylactic and therapeutical interventions. Novel targeted therapies present a challenge to recognize and treat rare adverse cardiovascular effects, usually without any evidence-based guidance. Therefore, scrupulous descriptions of clinical cases and drafting trials for real-world safety are paramount. We present a case of a 50-year-old Caucasian female who was diagnosed with cancer therapy-related cardiac dysfunction caused by combined BRAF and MEK inhibition in the treatment of malignant melanoma. The patient presented atypically with isolated severe fatigue without other specific cardiovascular symptoms. The findings of echocardiography and cardiac magnetic resonance indicated apical hypertrophic cardiomyopathy (AHCM), which is rare in our region. We stopped the oncological therapy and treated the patient with an ACE inhibitor, a beta-blocker, and an SGLT-2 inhibitor with a satisfactory effect. During the upcoming six months, the patient's state improved, and the control echocardiography ruled out an AHCM. As the patient's state rapidly improved after the withdrawal of BRAF and MEK inhibitors and the morphological finding was reversible, it can be theorized that the cardiotoxicity caused by the aforementioned drugs mimicked the phenotype of AHCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.